Database for the cross-sectional study: Seroprevalence and associated risk factors of Hepatitis C infection among Diabetic patients in South-Kivu, Eastern of the Democratic Republic of Congo
Description
This data provide from two diabetic healthcare centers of Bukavu City in the eastern part of the DRC, from December 2020 to December 2022. A questionnaire was submitted to diabetic patients in order to collect socio-demographic data, anamnestic data on risk factors for HCV infection, and clinical data on Diabetes Mellitus. These factors were analyzed based on their anti-HCV serological results. Microsoft Excel software was used to collect data and IBM SPPS 26 to make some analysis. Among 180 selected patients, 19 (10.6 %) tested positive for anti-HCV antibodies. After multivariate analysis, identified factors influencing these outcomes were male sex (ORa: 3.5, P=0.027), dental extraction (Ora: 7.6, P=0.001), and living in a privileged environment (ORa: 0.29, P=0.03). Factors related to DM as the type, the disease duration, or the usual type of treatment did not influence serological results.
Files
Steps to reproduce
This bi-centric study took place at the Bukavu Diabetes Centre (Centre Charles Mbogha) and the Bukavu University Clinics, situated in the city of Bukavu in the eastern part of the Democratic Republic of Congo (DRC). The research was conducted from December 2020 through December 2022. During the study period, we consistently interviewed all previously known or newly diagnosed diabetic patients who consulted or received follow-up care at the two research facilities. As a result, we enrolled 180 patients, including 39 at the CUB and 141 at the Bukavu Diabetes Center. In both hospitals, diabetes mellitus (DM) diagnosis was confirmed through documented use of oral antidiabetic drugs (OADs) or insulin, a random blood glucose level exceeding 200 mg/dL, or a fasting blood glucose level above 126 mg/dL on two separate occasions. Additionally, patients were given a questionnaire to gather sociodemographic data, anamnestic information on risk factors for HCV infection, and clinical data related to DM. We excluded diabetic patients who declined to participate in our questionnaire or provide a blood sample. Blood samples were collected using a sterile needle, stored in a sterile EDTA tube, and promptly transported to the lab. Each participant provided 3 mL of venous blood, immediately centrifuged upon arrival. Anti-HCV antibody screening was conducted with a high-performance rapid immunochromatographic kit (FaStep Polymed Therapeutics ©, USA), boasting near 100% sensitivity and specificity. Results were interpreted following the manufacturer's guidelines. Positive cases were verified using a third-generation ELISA kit (Lab kit Chemelex©, S.A., Barcelona, Spain) for the qualitative detection of anti-HCV antibodies.